Adjuvant Cyclophosphamide, Methotrexate, and Fluorouracil in Node-Positive Breast Cancer — The Results of 20 Years of Follow-up
- 6 April 1995
- journal article
- clinical trial
- Published by Massachusetts Medical Society in The New England Journal of Medicine
- Vol. 332 (14), 901-906
- https://doi.org/10.1056/nejm199504063321401
Abstract
Adjuvant combination chemotherapy with cyclophosphamide, methotrexate, and fluorouracil was administered after radical mastectomy for primary breast cancer with histologically positive axillary lymph nodes to assess whether it would improve treatment outcome as compared with surgery alone. Here we report a 20-year follow-up of this investigation.Keywords
This publication has 14 references indexed in Scilit:
- Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes. Ten-year resultsJAMA, 1995
- Second malignancies following CMF-based adjuvant chemotherapy in resectable breast cancerAnnals of Oncology, 1994
- Dose and Dose Intensity of Adjuvant Chemotherapy for Stage II, Node-Positive Breast CarcinomaThe New England Journal of Medicine, 1994
- Salvage Treatments in Relapsing Resectable Breast CancerRecent Results in Cancer Research, 1989
- Dose-Response Effect of Adjuvant Chemotherapy in Breast CancerThe New England Journal of Medicine, 1981
- The CMF program for operable breast cancer with positive axillary nodes:Updated analysis on the disease-free interval, site of relapse and drug toleranceCancer, 1977
- Combination Chemotherapy as an Adjuvant Treatment in Operable Breast CancerThe New England Journal of Medicine, 1976
- L-Phenylalanine Mustard (L-PAM) in the Management of Primary Breast CancerThe New England Journal of Medicine, 1975
- Asymptotically Efficient Rank Invariant Test ProceduresJournal of the Royal Statistical Society. Series A (General), 1972
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958